{"entity":{"id":"cid-078","kind":"drug","name":"CID-078","aka":[],"tldr":"CID-078 is an experimental oral macrocycle from Circle Pharma, in phase 1 trials for advanced solid tumours, small cell lung cancer and triple-negative breast cancer and other cancers.","summary":"CID-078 is an oral macrocycle (macrocyclic peptide) from Circle Pharma. An orally bioavailable macrocycle that blocks the RxL-mediated interactions of cyclins A and B, aimed at tumour cells whose cell cycle control is broken (for example high E2F activity). Its furthest stage is phase 1, for advanced solid tumours, small cell lung cancer, triple-negative breast cancer and ER-positive HER2-negative breast cancer after CDK4/6 inhibitors. ClinicalTrials.gov registers it in one study linked below. Phase 1 NCT06577987 is active, not recruiting (ClinicalTrials.gov). FDA orphan drug designation for small cell lung cancer, June 2025. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Circle Pharma: biospace.com","url":"https://www.biospace.com/press-releases/circle-pharma-announces-first-patients-dosed-in-phase-1-clinical-trial-of-first-in-class-oral-cyclin-a-b-rxl-inhibitor-cid-078-for-advanced-solid-tumors"},{"label":"Circle Pharma: biospace.com","url":"https://www.biospace.com/press-releases/circle-pharma-announces-first-patients-dosed-in-phase-1-clinical-trial-of-first-in-class-oral-cyclin-a-b-rxl-inhibitor-cid-078-for-advanced-solid-tumors"},{"label":"Circle Pharma: biospace.com","url":"https://www.biospace.com/press-releases/circle-pharma-receives-fda-orphan-drug-designation-for-cid-078-for-the-treatment-of-small-cell-lung-cancer"},{"label":"ClinicalTrials.gov: trials of CID-078","url":"https://clinicaltrials.gov/search?intr=CID-078"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer","sclc","tnbc","breast-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["circle-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06577987"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"CID-078","modality":"Oral macrocycle (macrocyclic peptide)","mechanism":"An orally bioavailable macrocycle that blocks the RxL-mediated interactions of cyclins A and B, aimed at tumour cells whose cell cycle control is broken (for example high E2F activity).","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/cid-078/","neighbours":{"cancer":[{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"company":[{"id":"circle-pharma","kind":"company","name":"Circle Pharma","route":"/companies/circle-pharma/"}],"trial":[{"id":"nct06577987","kind":"trial","name":"Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies","route":"/trials/nct06577987/"}]}}